Microbix Biosystems Inc. sees modest gains this week as it prepares for upcoming financial results.
Microbix Biosystems Inc. (MBX.TO) has seen a slight rise in its stock price this week, closing at C$0.29, which is a 1.64% increase. The company is getting ready to release its Q2 fiscal 2026 results on May 14, 2026. This announcement, along with other recent developments, has helped create a stable trading environment for the stock.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeAdvertisement
Market cap
$39.88M
52W high
$0.32
52W low
$0.21
1W change
-3.33%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 37.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+37.9% Upside
Current Price
C$0.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
39.4%
Annualized
90-Day Vol
50.0%
Annualized
Trend (90d)
+37.9%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.30 | C$0.26 – C$0.35 |
| 60 trading days | C$0.32 | C$0.26 – C$0.38 |
| 90 trading days | C$0.33 | C$0.26 – C$0.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on the upcoming Q2 results and consider the company’s recent performance metrics, such as revenue growth and market engagement, as potential indicators of future performance.
Microbix Biosystems Inc. Reports 29.17% YTD Gain
Despite ongoing losses, the company's stock has appreciated significantly since the start of the year, suggesting some optimism among investors.
Bull case
Positive revenue growth and upcoming product developments could indicate a turnaround for Microbix, making it an appealing option for long-term investors.
Bear case
The company continues to operate at a loss and faces challenges in achieving profitability, which may discourage risk-averse investors.
This Week's Price Action
Advertisement
Microbix Biosystems Inc. has shown modest performance this week, with its stock closing at C$0.29, reflecting a 1.64% increase over the past week. The stock has gained 29.17% year-to-date, indicating a positive trend despite some ongoing financial challenges.
Company News and Catalysts
While there was no major news this week, Microbix has been active in the diagnostics space, recently scheduling its Q2 fiscal 2026 earnings release for May 14, 2026. This anticipated event, along with a previous announcement of Q1 revenues showing a 13% increase, may spark investor interest.
Technical Picture
From a technical standpoint, Microbix's stock is currently trading above both its 50-day moving average of C$0.28 and its 200-day moving average of C$0.25, indicating positive momentum. The stock has a beta of 0.57, suggesting lower volatility compared to the overall market. The 52-week range of C$0.21 to C$0.34 indicates that the stock is trading at about 65% of its 52-week high, leaving room for potential growth.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
